In today’s increasingly fractured political environment, with heightened partisanship, Washington, DC, has become toxic. New ideas and common-sense solutions are rare and promoting issues without politicization is literally a full-time job. Interest groups are now finding policy opportunities for success in the state capitals. Some advocacy initiatives have found easier, and faster, wins for their organizational efforts at the state legislature level.

ONS President Susan Schneider, PhD, RN, AOCN^®, FAAN, was appointed to the Biden Cancer Initiative board of directors, among other experts in health care, business, finance, and technology. The Cancer Initiative also named ONS Chief Executive Officer Brenda Nevidjon MSN, RN, FAAN, to its advisory committee, comprised of 25 other experts aiming to transform the way cancer is detected, diagnosed, and treated by implementing new solutions to complex healthcare problems.  

The U.S. Congress continued its budget pattern in February, enacting another extension of the 2017 budget agreement into law on February 8, 2018. The current iteration of the budget law will raise caps on defense and non-defense spending over two years and keep the federal government running through March 23, but more importantly, it includes the following provisions of special interest to ONS.

Each day, more than 175 Americans die from an opioid-related overdose. Misuse of, addiction to, and overdose from opioids cost the United States $78.5 billion a year, “including the costs of health care, lost productivity, addiction treatment, and criminal justice involvement.”. Other alarming numbers abound: 21%–29% of patients who are prescribed opioids misuse them, 4%–6% of those transition to heroin, and 80% of people who use heroin first misused prescription opioids.

Thousands of pieces of legislation are introduced in each Congress, but only a small percentage make it through the entire process, especially in that first year. Bills that are not voted into law and signed by the president during that two-year period “die” when the second session is completed and Congress adjourns. According to congressional rules, “A bill may be introduced at any point during a two-year Congress. It will remain eligible for consideration throughout the duration of that Congress until the Congress ends or adjourns sine die.”

Breakthroughs and advancements in research and management have significantly changed the ways we understand how cancer works and how best to treat it. Recently, the Centers for Disease Control and Prevention (CDC) released its Annual Report to the Nation on the State of Cancer.

On November 3, 2017, the House of Representatives passed HR 3922, the Championing Healthy Kids Act, which reauthorizes the Children’s Health Insurance Program (CHIP) program for an additional five years. The act also reauthorizes public health programs. Previous funding for the CHIP program had expired September 30, 2017.

The Centers for Medicare and Medicaid Services (CMS) finalized a rule on November 1, 2017 that would reduce the current Medicare Part B drug payment to 340B hospitals from average sales price (ASP) plus 6% to ASP minus 22.5%.  However, rural sole community hospitals (SCHs), children’s hospitals, and PPS-exempt cancer hospitals are excluded from this payment adjustment in 2018.

In May 2017, Scott Gottlieb, MD, was named as the newest U.S. Food and Drug Administration (FDA) commissioner. He’s since shown a commitment to regulating tobacco and nicotine delivery systems—such as e-cigarettes—especially when it comes to children. In one of his public forums, Gottlieb spoke about the FDA’s commitment to continued oversight and regulation of these products and their distribution, a stance that’s drawn support from the medical community.

As part of its mission, ONS honors and maintains nursing’s historical and essential commitment to advocacy for the public good. Working collaboratively with policymakers, cancer and nursing community advocates, and other stakeholders at the local, state, federal, and international levels, ONS seeks to integrate the nursing perspective throughout the policymaking process and urges that oncology nurses be appointed to all relevant federal panels, committees, commissions, and boards. During its September conference call, the ONS Board of Directors focused on two key areas of ONS advocacy.

Former Speaker of the U.S. House of Representatives Tip O’Neill was fond of saying, “All politics is local.” What he meant was, if an elected official took care of the constituents back home, then whatever happened in Washington, DC, wouldn’t matter as much. Whatever issues most affected voters in the legislative district, then that is where members of Congress should spend their time.

On August 21, 2017, ONS submitted comments to Centers for Medicare and Medicaid Services Administrator Seema Verma, opposing the agency’s proposed policy to include Medicare Part B drugs in the calculation of Merit-Based Incentive Payment System (MIPS) payment adjustments.

ONS joined the Patient Quality of Life Coalition (PQLC) in signing a final comment letter to the Centers for Medicare and Medicaid Services (CMS) administrator, Seema Verma, on the agency’s proposed 2018 updates to the Quality Payment Program, CMS-5522-P. PQLC, which represents patients, health professionals, and healthcare systems, advocates for palliative care for patients and families facing serious illness.

As a national nursing organization with a specialty in cancer care, ONS occupies a unique space in the healthcare public policy environment. When nurses speak, decision makers listen, because nurses are the most trusted healthcare providers. This is not an insignificant fact to those who decide how to implement health policy decisions through law and the regulatory system.

After failing to garner support for the GOP’s healthcare bill in the Senate—known as the Better Care Reconciliation Act of 2017—Senate Majority Leader Mitch McConnell (R-KY) noted that the next strategy for repealing and replacing the Affordable Care Act (ACA) would be to repeal the legislation without any concrete healthcare bill to replace it. In 2015, the Senate already successful voted to repeal the ACA, but it was vetoed by former President Obama. According to McConnell, the 2017 repeal effort would provide a two-year window to ensure a stable transition.

Budgets are political documents. When we look at a spreadsheet, for many of us the numbers are jumbles and the lines begin to blur. But reviewed closely, budgets are the prioritization of federal policy.

On June 12, 2017, President Trump named Norman Sharpless, MD, as director of National Cancer Institute (NCI). Sharpless, formerly the director of the Lineberger Comprehensive Cancer Center at the University of North Carolina, is a practicing oncologist and cancer researcher. He will take over as for Doug Lowry, MD, who has been the NCI’s acting director since 2015.

There is a difference between campaigning and governing. Running for office is about putting out bold ideas and galvanizing a base of supporters who are energized by the opportunity for real change. It’s exhilarating and fluid. The momentum can be like a rock concert, and people are carried away with excitement about the future.

As the largest healthcare profession and the one most trusted by the public in the annual Gallup survey, nurses have the power to improve the health of communities throughout the country by bringing their expertise into the boardroom. However, we are an absent voice in so many of those boardrooms.

The National Institutes of Health (NIH) recently released the Annual Report to the Nation on the Status of Cancer, 1975–2014. According to the report, cancer death rates fell for 11 of the 16 most common cancers in men and 13 of the 16 most common cancers in women. Death rates fell for female breast cancer, lung cancer, colorectal cancer, and prostate cancers, among others. The report also notes that incidences of cancer decreased in men but plateaued for women in the same time period.

On March 15, 2017, the Trump administration released its first budget proposal, slashing federal spending in many areas of health care, education, environmental protection, and the sciences while increasing funding for defense and homeland security. The proposed budget would decrease spending for the Department of Health and Human Services by nearly 18%, which includes a 20% budget cut for the National Institutes of Health (NIH)—a decrease of nearly $6 billion. This stands to impact a number of cancer-related research programs developing new treatments and drugs through NIH funding.

On March 8, 2017, House Speaker Paul Ryan announced the American Health Care Act (AHCA), the Republican replacement plan for the Affordable Care Act (ACA). The AHCA is becoming known to many on Capitol Hill as Trumpcare, and it’s already facing stiff opposition from Democrats and Republicans alike. Many conservative Republicans are calling it Obamacare 2.0 and expected a full repeal of the ACA. Moderate Republicans are unlikely to support the bill, because it could potentially strand millions without insurance coverage provided by the ACA.

In a series of articles published by the Washington Post, patients living with cancer are speaking out against the potential harm that could impact cancer care with repeal of the Affordable Care Act (ACA). Told through each patient’s own experience with the ACA, the stories paint a vivid picture for lawmakers on Capitol Hill. By putting a face to those affected by repealing the ACA, this series may give representatives pause before they consider getting rid of the healthcare bill.